JP2016500673A5 - - Google Patents

Download PDF

Info

Publication number
JP2016500673A5
JP2016500673A5 JP2015535895A JP2015535895A JP2016500673A5 JP 2016500673 A5 JP2016500673 A5 JP 2016500673A5 JP 2015535895 A JP2015535895 A JP 2015535895A JP 2015535895 A JP2015535895 A JP 2015535895A JP 2016500673 A5 JP2016500673 A5 JP 2016500673A5
Authority
JP
Japan
Prior art keywords
antibody
seq
variable region
chain variable
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015535895A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016500673A (ja
JP6511396B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/063945 external-priority patent/WO2014058924A2/en
Publication of JP2016500673A publication Critical patent/JP2016500673A/ja
Publication of JP2016500673A5 publication Critical patent/JP2016500673A5/ja
Application granted granted Critical
Publication of JP6511396B2 publication Critical patent/JP6511396B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015535895A 2012-10-08 2013-10-08 アルファ−シヌクレイン認識抗体 Expired - Fee Related JP6511396B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261711204P 2012-10-08 2012-10-08
US61/711,204 2012-10-08
US201261719281P 2012-10-26 2012-10-26
US61/719,281 2012-10-26
US201361840432P 2013-06-27 2013-06-27
US61/840,432 2013-06-27
US201361872366P 2013-08-30 2013-08-30
US61/872,366 2013-08-30
PCT/US2013/063945 WO2014058924A2 (en) 2012-10-08 2013-10-08 Antibodies recognizing alpha-synuclein

Publications (3)

Publication Number Publication Date
JP2016500673A JP2016500673A (ja) 2016-01-14
JP2016500673A5 true JP2016500673A5 (enExample) 2016-12-01
JP6511396B2 JP6511396B2 (ja) 2019-05-15

Family

ID=50478052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015535895A Expired - Fee Related JP6511396B2 (ja) 2012-10-08 2013-10-08 アルファ−シヌクレイン認識抗体

Country Status (20)

Country Link
US (6) US9605056B2 (enExample)
EP (2) EP2903648B1 (enExample)
JP (1) JP6511396B2 (enExample)
KR (1) KR102163001B1 (enExample)
CN (2) CN109180812A (enExample)
AU (2) AU2013329381B2 (enExample)
BR (1) BR112015007882A2 (enExample)
CA (1) CA2886254A1 (enExample)
EA (1) EA034312B1 (enExample)
ES (1) ES2701406T3 (enExample)
IL (1) IL238192B (enExample)
MX (1) MX365099B (enExample)
MY (1) MY169086A (enExample)
NZ (1) NZ706337A (enExample)
PH (1) PH12015500767B1 (enExample)
SA (1) SA515360253B1 (enExample)
SG (1) SG11201502662QA (enExample)
UA (1) UA118441C2 (enExample)
WO (1) WO2014058924A2 (enExample)
ZA (1) ZA201502213B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
SI3067066T1 (sl) 2007-02-23 2019-08-30 Prothena Biosciences Limited Preventiva in zdravljenje sinukleinopatske in amiloidogene bolezni
KR101600733B1 (ko) 2011-10-28 2016-03-09 프로테나 바이오사이언시즈 리미티드 알파-시누클레인을 인식하는 인간화된 항체
JP6342333B2 (ja) 2012-01-27 2018-06-13 プロセナ バイオサイエンシーズ リミテッド α−シヌクレインを認識するヒト化抗体
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
WO2016061389A2 (en) 2014-10-16 2016-04-21 Genentech, Inc. Anti-alpha-synuclein antibodies and methods of use
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
TWI711631B (zh) * 2015-01-28 2020-12-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
TW202309093A (zh) 2016-06-02 2023-03-01 英商梅迪繆思有限公司 針對α-突觸核蛋白之抗體及其用途
AR110074A1 (es) 2016-11-15 2019-02-20 H Lundbeck As Agentes, usos y métodos para el tratamiento de la sinucleinopatía
US11237176B2 (en) 2016-12-02 2022-02-01 Prothena Biosciences Limited Infrared assay detecting secondary structure profiles of alpha-synuclein
JP7144755B2 (ja) 2016-12-16 2022-09-30 ハー・ルンドベック・アクチエゼルスカベット 薬剤、使用および方法
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
JP6908709B2 (ja) 2017-01-06 2021-07-28 エービーエル バイオ インコーポレイテッド 抗α−syn抗体およびその使用
JP7136790B2 (ja) * 2017-02-17 2022-09-13 ブリストル-マイヤーズ スクイブ カンパニー アルファ-シヌクレインに対する抗体およびその使用
JOP20190227A1 (ar) * 2017-03-31 2019-09-30 Biogen Int Neuroscience Gmbh تركيبات وطرق لعلاج اعتلالات السينوكلين
IL270361B2 (en) 2017-05-01 2025-04-01 Univ Pennsylvania Monoclonal antibodies against alpha-synuclein fibrils
WO2018204546A2 (en) 2017-05-02 2018-11-08 Prothena Biosciences Limited Antibodies recognizing tau
EP3672635A4 (en) 2017-08-23 2021-05-12 The Trustees of The University of Pennsylvania Monoclonal antibodies against pathological alpha-synuclein, and methods using same
WO2019071205A1 (en) 2017-10-06 2019-04-11 Prothena Biosciences Limited ANTI-TRANSTHYRETIN ANTIBODY
SG11202002490UA (en) 2017-10-06 2020-04-29 Prothena Biosciences Ltd Methods of detecting transthyretin
EP3717512A4 (en) 2017-11-29 2021-08-25 Prothena Biosciences Limited LYOPHILIZED FORMULATION OF A MONOCLONAL ANTIBODY AGAINST TRANSTHYRETIN
JP7212391B2 (ja) * 2017-12-14 2023-01-25 エービーエル バイオ インコーポレイテッド a-syn/IGF1Rに対する二重特異抗体およびその用途
GB201720975D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
WO2020003203A1 (en) * 2018-06-27 2020-01-02 Mor Research Applications Antibodies for the treatment of synucleinopathies and neuroinflammation
US20210347868A1 (en) * 2018-10-19 2021-11-11 Gabriel Pascual Anti-synuclein antibodies
TWI734279B (zh) 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
CN110172098B (zh) * 2019-05-27 2023-03-10 长春工业大学 抗α-突触核蛋白的单克隆抗体及其应用
US20220275097A1 (en) * 2019-07-02 2022-09-01 Shanghaitech University Antibody to leptin receptor
AU2020350769A1 (en) * 2019-09-20 2022-03-31 Denali Therapeutics Inc. Anti-alpha-synuclein antibodies and methods of use thereof
MX2022013173A (es) 2020-04-24 2022-11-30 Hoffmann La Roche Modulacion de enzimas y vias con compuestos de sulfhidrilo y sus derivados.
IL298215A (en) 2020-05-19 2023-01-01 Othair Prothena Ltd A multi-epitope vaccine for the treatment of Alzheimer's disease
TWI745993B (zh) 2020-06-04 2021-11-11 國立高雄大學 α-突觸核蛋白感測薄膜及其製造方法與用途
WO2022060236A1 (en) * 2020-09-17 2022-03-24 Qatar Foundation For Education, Science And Community Development ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED α-SYNUCLEIN AGGREGATES
KR20230087499A (ko) * 2020-09-18 2023-06-16 오타이르 프로테나 리미티드 알츠하이머 질환 치료용 멀티에피토프 백신
US12248291B2 (en) 2021-06-09 2025-03-11 Tyco Fire & Security Gmbh Central energy system with expert subplant models
US12105487B2 (en) 2021-12-06 2024-10-01 Tyco Fire & Security Gmbh Control system for building equipment with optimization search reduction based on equipment models and parameters
CN113912714B (zh) * 2021-12-15 2022-02-22 北京凯祥弘康生物科技有限公司 特异性结合α-突触核蛋白的抗体及其应用
US12292723B2 (en) 2022-01-21 2025-05-06 Tyco Fire & Security Gmbh Generating set of curtailment actions predicted to achieve net consumption target for a subperiod
US12099350B2 (en) 2022-03-04 2024-09-24 Tyco Fire & Security Gmbh Central plant with automatic subplant models
CN115032400A (zh) * 2022-03-28 2022-09-09 首都医科大学附属北京天坛医院 α-突触核蛋白在辅助诊断神经退行性疾病中的用途
US12282306B2 (en) 2022-04-29 2025-04-22 Tyco Fire & Security Gmbh Control system for building equipment with dynamic capacity constraints
US20240279316A1 (en) 2022-12-29 2024-08-22 Astrazeneca Ab Compositions and methods for treating alpha-synucleinopathies
KR20240176098A (ko) * 2023-06-14 2024-12-24 경상국립대학교산학협력단 알파 시누클레인 에피토프를 유효성분으로 포함하는 파킨슨병의 예방 또는 치료용 조성물

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0710719T3 (da) 1990-01-12 2007-07-09 Amgen Fremont Inc Frembringelse af xenogene antistoffer
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ アンティボディー テクノロジー リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DE69330523T4 (de) 1992-08-21 2012-08-23 Vrije Universiteit Brussel Immunoglobuline ohne leichte ketten
DE69329974T2 (de) 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE69620877T2 (de) 1995-02-06 2002-12-12 Genetics Institute, Inc. Arzneimittelformulierungen für il-12
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
ES2255280T3 (es) * 1998-07-03 2006-06-16 Innogenetics N.V. Diagnostico diferencial de la neurodegeneracion.
CN100405399C (zh) 1999-02-05 2008-07-23 三星电子株式会社 图像纹理恢复方法及其装置
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
EP1531864A4 (en) 2002-05-13 2006-08-23 Alexion Pharma Inc HUMANIZED ANTIBODIES TO THE VENEZOLAN HORSEMEN ENZEPHALITIS VIRUS
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
MXPA05005481A (es) 2002-11-29 2005-07-25 Boehringer Ingelheim Pharma Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada.
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
WO2005056759A2 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2578400C (en) 2004-11-10 2014-01-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
US20080300204A1 (en) 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
WO2007021255A1 (en) * 2005-08-09 2007-02-22 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US8148085B2 (en) 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
WO2008011348A2 (en) 2006-07-14 2008-01-24 Ac Immune S.A. Humanized antibody against amyloid beta
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
CA2678863A1 (en) 2007-02-23 2008-08-28 Schering Corporation Engineered anti-il-23p19 antibodies
JP5558834B2 (ja) * 2007-02-23 2014-07-23 ヤンセン アルツハイマー イミュノセラピー シヌクレイノパチーおよびアミロイド形成疾患(amyloidogenicdisease)の予防および処置
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
BRPI0808542A2 (pt) 2007-03-02 2014-08-26 Boehringer Ingelheim Pharma Aperfeiçoamento de produção de proteína
SI2132230T1 (sl) 2007-03-22 2014-07-31 Genentech, Inc. Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE
AU2008228823A1 (en) 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
EP2234600B1 (en) 2007-12-21 2014-08-20 F. Hoffmann-La Roche AG Antibody formulation
PT2237803E (pt) * 2007-12-28 2015-10-16 Prothena Biosciences Ltd Tratamento e profilaxia da amiloidose
WO2009123748A1 (en) 2008-04-05 2009-10-08 Single Cell Technology, Inc. Method of obtaining antibodies of interest and nucleotides encoding same
JP5747414B2 (ja) 2008-04-29 2015-07-15 バイオアークティック ニューロサイエンス アーベー α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
US20120276019A1 (en) 2008-07-25 2012-11-01 Diamedica Inc. Tissue kallikrein for the treatment of parkinson's disease
DE102008048129A1 (de) 2008-09-20 2010-04-22 Lfk-Lenkflugkörpersysteme Gmbh Flugkörper mit zumindest einem Bremsfallschirm sowie Befestigungsvorrichtung zur Befestigung eines Bremsfallschirms an einem Flugkörper
CN102227440A (zh) 2008-09-30 2011-10-26 雅培制药有限公司 改良的抗体文库
WO2010053587A2 (en) 2008-11-07 2010-05-14 Mlc Dx Incorporated Methods of monitoring conditions by sequence analysis
DK2370466T3 (en) 2008-12-19 2015-08-03 Univ Zuerich Humane anti-alpha-synuclein-autoantistoffer
CN109172813B (zh) 2009-07-28 2022-09-02 武田药品工业株式会社 用于治疗戈谢病的组合物和方法
WO2011025826A1 (en) 2009-08-26 2011-03-03 Research Development Foundation Methods for creating antibody libraries
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011090720A2 (en) 2009-12-29 2011-07-28 Dr. Reddy's Laboratories Ltd Purification of proteins
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN102939305B (zh) 2010-04-08 2016-08-17 Jn生物科学有限责任公司 对cd122的抗体
BR112012030311A2 (pt) 2010-06-08 2017-01-24 Genentech Inc anticorpo
WO2011155607A1 (ja) 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗tim-3抗体
EP2593128B1 (en) 2010-07-15 2018-01-10 Adheron Therapeutics, Inc. Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods
KR20130142128A (ko) 2010-10-11 2013-12-27 애브비 인코포레이티드 단백질의 정제 방법
US20140050733A1 (en) * 2011-02-07 2014-02-20 Dale B. Schenk Apoe immunotherapy
WO2012160536A1 (en) 2011-05-26 2012-11-29 Dr Reddy's Laboratories Limited Antibody purification
WO2012177997A1 (en) 2011-06-22 2012-12-27 The General Hospital Corporation Treatment of proteinopathies
CN107090038A (zh) 2011-06-30 2017-08-25 霍夫曼-拉罗奇有限公司 抗c‑met抗体配制剂
KR101600733B1 (ko) 2011-10-28 2016-03-09 프로테나 바이오사이언시즈 리미티드 알파-시누클레인을 인식하는 인간화된 항체
PT3091029T (pt) 2011-10-31 2023-02-03 Hoffmann La Roche Formulações de anticorpos anti-il13
JP6342333B2 (ja) 2012-01-27 2018-06-13 プロセナ バイオサイエンシーズ リミテッド α−シヌクレインを認識するヒト化抗体
CN104520329A (zh) 2012-08-29 2015-04-15 霍夫曼-拉罗奇有限公司 血脑屏障穿梭体
US8925815B2 (en) 2012-09-05 2015-01-06 Symbol Technologies, Inc. Checkout system for and method of preventing a customer-operated accessory reader facing a bagging area from imaging targets on products passed through a clerk-operated workstation to the bagging area
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US10084674B2 (en) 2015-09-09 2018-09-25 International Business Machines Corporation Virtual desktop operation and data continuity preservation

Similar Documents

Publication Publication Date Title
JP2016500673A5 (enExample)
JP2016512551A5 (enExample)
JP2016063812A5 (enExample)
JP2020500538A5 (enExample)
HRP20190008T4 (hr) Prevencija i liječenje sinukleinopatske i amiloidogene bolesti
JP2019521649A5 (enExample)
JP2017518258A5 (enExample)
JP2013198490A5 (enExample)
JP2015522252A5 (enExample)
RU2017125758A (ru) Антитела к с5 и способы их применения
RU2016110891A (ru) Антитела к fcrh5, их иммуноконъюгаты и способы их применения
JP2013520996A5 (enExample)
JP2017052784A5 (enExample)
JP2010526028A5 (enExample)
JP2018506277A5 (enExample)
JP2019525728A5 (enExample)
HRP20191608T1 (hr) Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida
JP2014205674A5 (enExample)
FI3389699T3 (fi) Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
RU2016100892A (ru) Антитела против tweakr и их применение
JP2017536102A5 (enExample)
JP2019504032A5 (enExample)
RU2017128882A (ru) Антитела к биотину и способы их применения
HRP20221471T1 (hr) Protutijela anti-fgfr3 i postupci za njihovu uporabu
RU2014134747A (ru) Гуманизированные антитела, которые распознают альфа-синуклеин